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Background: Evidence suggests that prolonged and enhanced pro-inflammatory signaling, 
modulated by the NLRP3 inflammasome, plays a crucial role in the pathophysiology of several 
different types of cardiovascular diseases such as acute myocardial infarction (AMI), adverse 
ventricular remodeling, and heart failure (HF). Consequently, we hypothesize that attenuating the 
enhanced inflammatory response using a pharmacological NLRP3 inflammasome inhibitor 
would decrease cell death, improve cardiac function, limit adverse cardiac remodeling, and 
overall reduce the risk of developing ischemic heart failure. We investigated the role of the 
NLRP3 inflammasome after a nonreperfused AMI, by studying the effects of inhibiting the 
NLRP3 inflammasome.  
 
Methods: In this study we used a mouse model of acute myocardial infarction (AMI) due to 
permanent coronary artery ligation. We assessed cardiac function in mice using transthoracic 
echocardiography 3 days after inducing a large nonreperfused AMI, via permanent ligation of the 
LAD coronary artery,  and select mice with large nonreperfused anterior infarct (> 4 akinetic 





diastolic diameter  [LVEDD] > 4.4 mm) and systolic dysfunction (left ventricular ejection 
fraction [LVEF] < 40%). The mice were then randomly assigned to one of four groups.  
Group 1 (n=8) consisted of mice with an AMI and were fed OLT1177, a NLRP3 inflammasome 
inhibitor admixed with the chow in the diet (3.75 gr/kg) for 10 weeks. Group 2 (n=7) consisted 
of mice with an AMI and were fed OLT1177, a NLRP3 inflammasome inhibitor admixed with 
the chow in the diet (7.5 gr/kg) for 10 weeks. Group 3 (n=7) consisted of mice with AMI that 
were fed a standard diet (without OLT1177) for 10 weeks. Group 4 (n=6) consisted of mice that 
underwent a sham operation and had no AMI and were fed a standard diet for 10 weeks. We 
repeated transthoracic echocardiography assessments 4-weeks and 10-weeks after coronary 
artery ligation surgery with an assessment of changes in LVEF, along with isoproterenol 
challenge in order to measure contractile reserve, a surrogate for cardiorespiratory fitness. The 
surviving mice underwent LV catheterization, a terminal procedure, in order to evaluate left 
ventricular diastolic function in vivo by measuring left ventricular end-diastolic pressure.    
 
Results: At the end of 10 weeks, 2 of 10 mice (20%) had died in OLT 3.75 gr/kg group, as 
compared with 2 of 9 (22%) in the OLT 7.50 gr/kg group, 3 of 10 mice  (30%) in the control diet 
group, and 0 of 6 mice (0%) in the sham-operated group. Treatment with OLT 3.75 gr/kg or 7.50 
gr/kg led to preservation of contractile reserve (percent increase in LVEF after isoproterenol 
challenge [+3311% or +406% vs +97 % in standard diet; P<0.05 and P<0.005 respectively). 
Treatment with OLT 3.75 gr/kg or 7.5 gr/kg also led to preservation of diastolic function (left 
ventricular end-diastolic pressure 3.20.5 mmHg, or 4.50.5 mmHg vs 10.01.6 mmHg in 
standard diet; P<0.005 and P<0.009). These effects were independent of effects on ventricular 





Conclusions/implications: The results presented in this study show that NLRP3 inhibition with 
OLT1177 can preserve ß-adrenergic responsiveness and prevent left ventricular diastolic 
dysfunction in large nonreperfused anterior AMI thereby reducing the risk of developing post-
infarct heart failure.  
 
Keywords: Acute myocardial infarction, cardiac remodeling, heart failure, NLRP3 


















 This thesis document has been organized to include a relevant review of background 
information regarding acute myocardial infarction, ventricular remodeling, and heart failure. An 
overview is also presented on the physiological processes that follow a myocardial infarction that 
occurs in an inflammatory response mediated by the NLRP3 inflammasome. Lastly, this article 
provides a brief overview of a novel inflammasome inhibitor (OLT1177) and discusses its 
potential use as a pharmacological intervention targeting inflammation in a nonreperfused AMI 



















CHAPTER 1: Motivation and Significance 
 
1.1 Background 
 The American Heart Association approximates that every 40 seconds, an American has a 
heart attack (MI). Correspondingly, the number of acute myocardial infarctions is rising, and as a 
result has become one of the most prevalent causes of hospitalization and death in the United 
States (Benjamin et al., 2019). Even so, thanks to medical advancements, and the continuous 
improvement in effective and prompt medical treatment, patients are surviving and living longer 
after a myocardial infarction(s). However, just as more people are living longer after an MI, there 
has been a continuous rise in the prevalence of post-MI heart failure (Benjamin et al., 2019) 
 According to current scientific literature, infarcted myocardium in most patients can be 
salvaged if coronary arterial flow and patency is restored promptly (Cohen et al., 2010). 
Conversely, evidence-based findings show that if treatment is delayed, myocardial infarct size or 
rate of myocardial cell death/injury increases resulting in a higher risk of developing a 
maladaptive form of cardiac remodeling that is mediated by neurohormonal and inflammatory 
signaling pathways. This form of adverse cardiac remodeling is one of many factors that over 
time contributes to the risk of developing post-MI heart failure, both for short-term and extended 
periods of time (Azevedo et al., 2016). For this reason, therapies developed in the last 20 years, 
such as those that target neurohormonal signaling pathways, and current/novel therapies that are 
targeting inflammatory signaling pathways are being developed and continually improved upon 






1.1.1 Acute Myocardial Infarction (AMI) 
 
 Under normal physiological conditions, the heart’s atria and ventricles work in unison to 
carry out the hearts main function – pumping blood in a unidirectional manner throughout the 
body. This highly coordinated, continuous, and life-long form of perfusion is controlled by the 
heart’s conduction system consisting of myogenic (spontaneous contraction initiated by the 
heart) electrical impulses that begin at the sinoatrial (SA) node located in the right atrium. This 
impulse next spreads throughout the walls of both right and left atria, then to the atrioventricular 
(AV) node, AV bundle, and to the rest of the Purkinje muscle fibers in right and left ventricles. 
Once these ventricle chambers receive the impulse myocardial cells contract, creating a pressure 
that is capable of opening heart valves and pumping blood through the pulmonary artery and to 
the lungs for blood oxygenation, as well as through the aorta and arterial circulation; whereby the 
body’s muscles and tissues, including the heart’s myocardium via coronary arteries, receives 
oxygenated blood and nutrients. 
 Although the SA node works as the “heart’s natural pacemaker” capable of affecting and 
altering heart rate, blood pressure, contractility, and coronary artery flow; there are other factors 
that also play a role in regulation. These factors include nerve impulses from the autonomic 
nervous system (parasympathetic and sympathetic) and neurohormonal effects regulated by the 
sympathetic nervous system (SNS) and the renin-angiotensin-aldosterone system (RAAS). 
Together in a dynamic manner, the heart’s conduction system, autonomic nervous system, and 
neurohormonal effects help create a balance between the heart’s O2 demand and O2 supply. 
  An instance when this balance is altered, occurs when a coronary artery is partially or 
completely occluded resulting in a decrease of O2 supply to the myocardium (ischemia) that can 





coronary artery can swiftly lead to ischemic injury, and the impairment of myocardial 
metabolism (decreased cellular ATP levels) resulting in cell swelling and necrotic cell death in 
the ischemic area, and apoptosis in the ischemic tissue, the surrounding border zone, and non-
ischemic myocardial area (Abbate et al., 2002). 
 A key feature of cell death during an AMI is that it progresses in the left ventricle wall 
from the subendocardium toward the myocardium and epicardium in a transmural manner (M. 
Tanaka, V. Richard, C. Murry, R. Jennings, Reimer, 1993). The reasons for this cell death 
progression are due to the subendocardium being subjected to the highest pressure coming from 
the ventricular chamber filled with blood, having fewer collateral blood vessel connections, and 
to being perfused by coronary arteries that must first reach and pass through layers of contracting 
myocardium (Lilly, 2013). Additionally, cardiac tissue that is directly supplied by an occluded 
coronary artery will die quickly, whereas tissue adjacent to the myocardial infarct can survive 
temporarily under ischemic conditions, due to collateral vessels from neighboring non-occluded 
coronary arteries. Nevertheless, as more time passes under ischemic conditions, tissue adjacent 
to the myocardial infarct will unavoidably succumb to infarction/necrotic cell death (Lilly, 
2013). Together, the prolongation and severity of ischemia, impairment of myocardial 
metabolism, and necrotic cell death will lead to a cascade of events such as acute inflammation 
and immune cell recruitment which further increases cell death, inflammatory signaling, and loss 
of cardiac function.  Additionally, characteristic AMI symptoms do occur in the form of 
systolic/diastolic dysfunction, arrhythmia, chest pain, shortness of breath, changes in protein 
levels (cTnI, cTnT, and CK-MB) proportional to the amount of cardiac tissue that is damaged, 






1.1.2 Diagnosis of Acute Myocardial Infarction (AMI) 
 While there exist various subtypes of myocardial infarction related to its causes, the two 
most prevalent types are type I and type II AMI. A type I AMI, also known as a spontaneous MI, 
refers to a myocardial infarction caused by an atherothrombosis or blood clot forming in the 
lumen of a coronary artery and causing a sudden (partial or complete) occlusion which 
significantly decreases the flow of blood through the coronary artery. What precedes the 
formation of an atherothrombosis is the loss of integrity that occurs at the level of an 
atherosclerotic plaque’s protective covering (fibrous cap) resulting in the release of its 
thrombogenic and lipid-rich contents into the lumen of a coronary artery following plaque 
erosion, plaque rupture, fissuring, or dissection (Lilly, 2013). Following the exposure of the 
plaque’s content coming into contact with the blood, the activation of the coagulation cascade, 
and the formation of an atherothrombosis follows (Burke et al., 2014). Conversely, a type II 
AMI, also known as secondary MI, refers to a myocardial infarction that is not the result of a 
primary coronary artery event/atherothrombosis. Examples of the causes that lead to type II 
AMIs are the following: coronary artery spasm, coronary embolism, anemia, and hypotension 
(Thygesen et al., 2012). 
 When diagnosing an acute myocardial infarction, clinicians rely on identifying the 
following criteria: acute onset of angina (chest pain), symptoms of ischemia along with 
electrocardiograms showing new ST-elevation, abnormal Q wave, or new left bundle branch 
block (LBBB), and evidence of myocardial necrosis through the use of blood tests to detect a rise 
and/or fall of cardiac biomarker values such as cardiac troponin (cTn) and creatine kinase 
myocardial band (CK-MB) (Thygesen et al., 2012). The reasoning behind utilizing these 





these biomarkers into the bloodstream at a greater rate. On the other hand, if a cardiac muscle 
injury has improved, via reperfusion treatments, these cardiac biomarkers would decrease 
(Antman et al., 1996). As a result, the assessment of cardiac biomarkers like cardiac troponin 
(cTnI and cTnT) levels in the blood have been implemented and used as a diagnostic indicator of 
myocardial damage, and thus useful in diagnosing and managing the type of myocardial 
infarction or other various forms of heart muscle damage presently taking place in a 
patient(Lilly, 2013). As an added piece of information, the initial rise in troponin levels in the 
blood occurs within 2-3 hours after an MI and according to a recent finding, levels may persist 
and be elevated for up to 2 weeks after an MI (Aydin et al., 2019) 
 Another form of assessing or diagnosing an acute myocardial infarction is through 
imaging techniques such as transthoracic echocardiography (TTE). As a non-invasive imaging 
technique, transthoracic echocardiography (TTE) allows one to detect the following: the number 
of segments displaying regional wall abnormalities during a myocardial infarction, the size of an 
infarct, the progress of a healing or healed myocardial infarction, as well as adverse ventricular 
remodeling resulting from a myocardial infarction. (Abouzaki & Abbate, 2016). An additional 
non-invasive imaging technique is the cardiac magnetic resonance imaging (cMRI or CMR). The 
application of cMRI with the use of gadolinium enhancement allows clinicians to take more 
precise measurements and tissue characterization than TTE, such as being capable of 
distinguishing between reversible and irreversible myocardial injury (Abouzaki & Abbate, 2016)  
(Fieno et al., 2000). Thus, it is oftentimes labeled as the gold standard in diagnosing and 
evaluating the progression of an AMI (Bhatt et al., 2017). 
 After an assessment of the AMI has been made, the main goal of treatment is to salvage 





necrotic cell death. To accomplish this, focus is placed on timely/prompt reperfusion methods 
like the following: antithrombotic drugs to dissolve the thrombus (thrombolytics), and 
percutaneous coronary intervention (PCI) that includes the utilization of emergency 
catheterization and coronary stents (or drug-eluting stents) to help open or increase the diameter 
necessary to restore blood flow in plaque-occluded coronary arteries.  
 All things considered, the combined utilization of electrocardiograms, cardiac biomarker 
tests, and non-invasive imaging techniques, are vitally essential. Thanks to these medical 
advancements, clinicians are better able to diagnose AMIs, evaluate infarct size and develop 
appropriate and timely reperfusion strategies, that are not only vital in salvaging damaged 
myocardial tissue, but also important in preventing adverse cardiac remodeling and post-MI 
heart failure, thereby improving survival rates and prognosis of patients who have undergone an 
AMI (Bhatt et al., 2017) 
 
1.1.3 Adverse Ventricular Remodeling   
 Following myocardial ischemia and subsequent acute myocardial infarction, treatment in 
the form of reperfusion and pharmacological medications is time-sensitive and will affect the 
prognosis of patients undergoing a myocardial infarction. Consequently, patients, who receive 
reperfusion treatment past optimal/therapeutic treatment times, will be at higher risk of 
developing larger transmural infarcts, adverse ventricular remodeling, wall rupture, and even 
heart failure (Abouzaki & Abbate, 2016)  
 To prevent these detrimental outcomes and to maintain circulatory function, namely 
stroke volume (SV) and cardiac output (CO), the heart employs an acute compensatory response 





term ventricular remodeling refers to morphologically characteristic changes that include dilation 
of the ventricle, disproportionate thinning and dilation of the infarcted region, formation of a 
scar, and geometrical changes in the overall LV shape (i.e. ellipsoid to more spherical shape) 
(Weisman et al., 1985). These compensatory effects are regulated by the Frank-Starling 
mechanism, neurohormonal activation (SNS and RAAS), and the body’s innate immune 
inflammatory response. 
 During the first 3-4 days after an AMI, myocardial cell death, loss of contractility 
(systolic dysfunction), and area of necrosis progresses in the LV. In response to myocardial cell 
death, an influx of inflammatory cells removes cellular debris and promotes the destruction of 
collagen scaffolding that helps maintain ventricular shape. (Cleutjens et al., 1995). Additionally, 
it is important to note that the degree of this inflammatory response to myocardial injury varies 
according to the size of the infarct and to each individual’s genetic and epigenetic factors that 
control inflammation (Stylianou, 2019). 
 Furthermore, ventricular remodeling can occur with the intent of preserving the heart’s 
cardiac output (CO) by way of stretching LV myocardial fibers, resulting in regional thinning 
and acute dilatation of viable myocardium in the infarcted areas. Consequently, the dilatation of 
the LV myocardium increases the preload/amount of blood returned to the heart (LVEDV) via 
the Frank-Starling mechanism. This increase in preload, from LV dilation and stretching of LV 
myocardial fibers, creates an increased tension between cardiomyocytes’ filaments (Mann, 
2011), that leads to an increase in the force of contraction (inotropic activity) from ß-adrenergic 
receptor stimulation, thereby increasing stroke volume and adequately maintaining the heart’s 





 Weeks to months following an AMI, progressive ventricular remodeling, LV dilatation 
coupled with non-compliant scar formation, increases wall stress in the LV chamber, and causes 
myocardium to undergo eccentric hypertrophy (M. Pfeffer E. Braunwald, 1990). This increase in 
wall stress, according to the Laplace relationship can lead to further LV dilatation that causes the 
heart to become less elliptical and more spherical (Westman et al., 2016b) 
 Other factors that drive adverse cardiac remodeling are neurohormonal activation 
regulated by the sympathetic nervous system (SNS) and the renin-angiotensin-aldosterone 
system (RAAS). In response to decreased CO, the SNS releases epinephrine and norepinephrine 
which affects the heart by increasing, peripheral vascular resistance, HR, SV, BP, and 
contractility when ß-adrenergic receptors are stimulated. It is particularly useful in helping the 
body and tissues meet increases in O2 demand whether during exercise or even during an AMI. 
Conversely, persistent SNS activation by way of catecholamines leads to detrimental effects on 
the recovering or post-infarcted heart such as hypertrophy, enhanced apoptotic pathways, and 
reduced cardiac function that all promote fibrosis and further damage (Bhatt et al., 2017) 
 Chronic SNS activation also promotes the renin-angiotensin-aldosterone system (RAAS) 
activation. Through the RAAS, the enzyme renin cleaves angiotensinogen to angiotensin I which 
is then cleaved by angiotensin-converting enzyme (ACE) to help convert angiotensin I to 
angiotensin II. The increased expression of angiotensin II promotes vasoconstriction and has a 
direct cytotoxic effect on cardiac myocytes, leading to the acceleration of apoptosis and the 
promotion of cell hypertrophy. In addition, studies in animal models have shown that angiotensin 
II infusion leads to increases in perivascular and interstitial collagen content (Sigusch et al., 





impairment of arterial compliance, increases in total peripheral resistance (TPR), and HTN 
(Lilly, 2013). 
 All things considered, as time passes adverse ventricular remodeling modulated by 
inflammation, non-compliant scar formation, and neurohormonal activation can lead to further 
LV dysfunction and reduced cardiac output that can result in volume overload and develop into 
ischemic heart failure (Lilly, 2013).  
 
1.1.4 Heart Failure    
 Heart failure (HF) is a disease whose onset can be chronic (compensated heart failure) or 
acute (decompensated heart failure). As a clinical syndrome, heart failure is often attributed to 
being a final common pathway of many cardiac diseases resulting in a decrease in cardiac output 
that causes patients to experience dyspnea, fatigue, poor-exercise intolerance, and volume 
overload. In addition, heart failure patients can also display orthopnea, paroxysmal nocturnal 
dyspnea (PND), edema, and abdominal distention (ascites). The manner in which a decreased 
cardiac output can lead to heart failure symptomatology results from many functional or 
structural heart disorders that can impair the ventricles’ systolic and diastolic function. Some of 
these disorders, such as coronary artery disease (CAD), hypertension (HTN), dilated 
cardiomyopathy (DCM), or an AMI, affects the heart’s ability to pump blood, to the point of no 
longer being able to meet the body's metabolic O2 demand. Along those lines, more than 2/3 of 
all HF cases can be attributed to 4 underlying conditions: Ischemic heart disease (CAD), chronic 
obstructive pulmonary disease (COPD), hypertensive heart disease, and rheumatic heart disease. 





 There are two types of HF that are categorized based on left ventricular ejection fractions 
(LVEF). The first type of heart failure, heart failure with reduced EF (HFrEF), is a form of heart 
failure that is directly caused by systolic dysfunction and the ventricle’s diminished capacity to 
eject blood. The systolic dysfunction that occurs in HFrEF is characterized by a left ventricular 
ejection fraction < 40% along with concurrent HF symptoms. Furthermore, systolic dysfunction 
is caused by secondary cardiac issues that alter myocardial cell function, through inflammatory 
processes, cell death, and fibrosis. As a result, damage caused by MI is commonly associated 
with HFrEF (Gerber et al., 2016). The second type of HF, heart failure with preserved EF (LVEF 
> 50%), refers to heart failure symptoms caused by diastolic dysfunction resulting from the 
ventricle’s diminished capacity to relax and fill during diastole. Conditions that lead to diastolic 
dysfunction include cardiac issues that increase the stiffness of the ventricular wall by way of LV 
hypertrophy, or fibrosis. A common sign displayed by HFpEF patients is vascular congestion 
due to elevated diastolic pressure in the ventricles being transmitted in a retrograde manner to the 
pulmonary and systemic veins (Lilly, 2013). As a whole, the distinction between HFrEF and 
HFpEF and their etiologies continues to be vital in guiding therapeutic interventions for the 
growing number of HF patients.    
 According to clinical guidelines, there is no single diagnostic test for HF. Instead, 
diagnosing heart failure involves a combination of physician assessments, biomarker studies, 
imaging data from non-invasive techniques (TTE, cMRI), or invasive hemodynamic 
catheterization (Yancy et al., 2016). After completing these assessments, clinicians are able to 
evaluate at-risk and current heart failure patients by way of the American College of Cardiology 
Foundation/American Heart Association and New York Heart Association functional 





progression of disease, whereas the NYHA classes place emphasis on an individual’s exercise 
capacity and their present symptomatic status of the disease (Yancy et al., 2016). By focusing on 
different aspects of HF, both classification systems are important in helping to provide 
appropriate guideline-directed medical therapy (GDMT).  
 Currently, GDMT for heart failure is complex and utilizes an array of therapies that can 
be pharmacological, interventional, or surgical. The goal of these therapies is to regulate and 
keep the once compensatory mechanisms in physiological range, manage symptoms, and prevent 
and limit further decline. However, even with current and improved guideline-directed medical 
therapies, the absolute mortality rate for patients with HF is approximately 50% within the first 
five years of diagnosis (Roger et al., 2012). It appears that once a patient reaches HF, what 
follows is a vicious trajectory of morbidity and mortality that involves multiple hospital 
readmissions, numerous medications prescribed, and debilitating symptoms that significantly 
affects the quality of life. For these reasons, medical research continues to strive to find ways to 
not only improve GDMT but also prevent the development of HF, whether through 
improvements in diet, activity, and medications.  
 One way that GDMT seeks to improve upon is in the utilization of pharmacological 
therapies to target risk factors such as ischemic heart disease and compensatory mechanisms that 
lead to adverse ventricular remodeling and heart failure. Currently neurohormonal 
blockade/antagonism is the cornerstone of GDMT for the prevention of adverse ventricular 
remodeling in patients with MI (Ponikowski et al., 2016). Seeing that compensatory mechanisms 
are regulated by neurohormonal signaling pathways, many types of neurohormonal antagonist 
medications have been developed such as ACE inhibitors, angiotensin-receptor blockers (ARB), 





 Furthermore, due to preclinical (Toldo et al., 2019) and clinical (B. W. Van Tassell et al., 
2017) findings, evidence has been mounting in support of classifying inflammatory responses as 
a major contributor in the pathophysiology of MI, adverse cardiac remodeling, and HF (Van 
Linthout & Tschöpe, 2017). As a result, there has been a gradual shift in ideology from targeting 
solely neurohormonal and atherosclerotic mechanisms, to also targeting and attenuating the 
inflammatory processes during the stages that lead up to HF as well as after its onset, with the 
goal of improving symptoms and preventing HF progression.   
 One particular human clinical trial that has spearheaded the shift in ideology to target and 
label inflammation as a pathogenic contributor to cardiovascular disease, is the Canakinumab 
Anti-inflammatory Thrombosis Outcomes Study (CANTOS). In 2011, this large-scale, 
randomized, double-blind, placebo-controlled clinical trial began. In total it consisted of testing 
10,061 patients in 39 countries with previous AMI and high levels of CRP (>2mg/L), and at 
median follow-up of 3.7 years to see whether an anti-inflammatory drug, canakinumab -- a 
monoclonal antibody blocking interleukin-1ß (IL-1ß), could prevent and lower rates of recurrent 
cardiovascular events. The results, published in 2017, showed that patients taking canakinumab 
(150 mg/3 months) had reduced CRP levels and significantly reduced cardiovascular events 
independent of lipid levels, thus providing proof-of-principle that adequate inhibition of the 
inflammatory pathway from IL-1ß to IL-6 to CRP can significantly reduce cardiovascular events 
(Ridker et al., 2017) (Abbate, 2017). 
 
1.1.5 Inflammation in AMI    
 Inflammation is mainly an innate immune response that is highly coordinated. Its purpose 





healing at the site of injury or infection through leukocyte chemotaxis. With an etiology that can 
be infectious or non-infectious, inflammation can occur in response to various pathogenic factors 
like bacteria, viruses, and other microbes, or due to non-infectious triggers and signals resulting 
from tissue injuries such as trauma, physical injury, toxins, burns, or cell death (that occurs 
following a myocardial infarction) (Chen et al., 2018). Additionally, there are specific organs 
that exhibit organ-specific inflammatory responses that are modulated according to an 
individual’s immune capabilities as well as to the site of injury or infection. These organs include 
the heart, pancreas, liver, kidney, lung, and brain (Chen et al., 2018). 
 The responsibility of initiating and regulating the acute inflammatory response relies 
mostly on innate immunological cells such as neutrophils, tissue macrophages derived from 
circulating monocytes, and dendritic cells. In order to destroy and remove pathogens and cell 
debris, these innate immunological cells detect molecular signals through the use of germ-line-
encoded pattern-recognition receptors (PRRs) (Hirayama et al., 2018). PRRs are capable of 
detecting/recognizing microbial structures such as pathogen-associated molecular patterns 
(PAMPs) and damage-associated molecular patterns (DAMPs) that can lead to the formation of 
cytosolic macromolecular complexes (inflammasomes) and the downstream release of 
inflammatory mediators (chemokines and cytokines: IL-1ß, IL-6 TNF-⍺ etc.). The release of pro-
inflammatory mediators from the cell are what lead to increased vascular permeability resulting 
in the following: increased recruitment of leukocytes to the site of injury/infection, the release of 
inflammatory markers/proteins (e.g. CRP, fibrinogen) from the liver, as well as the clinical signs 






 Pattern-recognition receptors are subdivided into two major classes based on their 
cellular localization (Bedard et al., 2019). The first major class of PRRs is found in the cell 
membrane: Toll-like receptors (TLRs) and C-type lectin receptors (CLRs) (Medzhitov, 2010). 
The second class of PRRs is cytoplasmic PRRs and they include retinoic acid-inducible gene 
(RIG-I-Like) receptors, the AIM2-like receptors (ALRs), and the NOD-like receptors (NLRs) 
(Bedard et al., 2019). Among these cytoplasmic PRR sensors NLRs, ALRs and pyrin trigger a 
distinct defense mechanism that leads to the assembling of cytosolic macromolecular protein 
complexes, known as inflammasomes, which are responsible for utilizing caspase-1 to process 
pro-interleukin-1ß (IL-1ß) and pro-IL-18 to their mature forms. Thus, the importance in 
understanding the functioning/physiological mechanisms of PRRs is indispensable seeing that 
PRRs and inflammasomes are what allow innate immune cells to initiate acute inflammatory 
responses thereby acting as the body’s first line of defense against PAMPs and DAMPs in the 
extracellular milieu (Martinon et al., 2002).  
 Much of what we know from the inflammatory response that follows a myocardial 
infarction comes from preclinical studies on mice. In Figure 1 we see a descriptive diagram 
demonstrating the types of inflammation that follows an AMI. Beginning with the inflammatory 
phase in which an intense sterile inflammation leads to immune cells being recruited to serve in 
digesting and removing damaged cells (≈0 - 4 d in mice), followed by a reparative and 
proliferative phase in which neovascularization occurs along with inflammation being 
suppressed and resolved (≈4 -14 days) (Prabhu et al., 2017).  
 As important as it is for immune cells to initiate an acute inflammatory response, it is also 
important for them to have mechanisms in place to resolve inflammation when no longer 





mechanisms to terminate an inflammatory response: upregulation of anti-inflammatory 
cytokines/molecules (such as IL-10), downregulation of pro-inflammatory cytokines, short half-
life of inflammatory mediators, and the cessation of tissue infiltration by neutrophils that results 
in the initiation of programmed cell death (apoptosis) and subsequent neutrophil clearance by 
phagocytosis from macrophages (Freire & Van Dyke, 2013). Furthermore, an inflammatory 
response is considered resolved with the departure of macrophages through the lymphatic system 
(Ortega-Gómez et al., 2013). In addition to the processes that resolve inflammation during the 
reparative phase, scar formation mediated by fibroblasts and myofibroblasts occurs, due to the 
heart’s limited capacity to regenerate after injury (≈4 -14 days).  
 However, in the weeks to months that follow an AMI, if post-infarction inflammation is 
not suppressed and continues, then this form of post-infarction chronic inflammation coupled 
with overactive fibrosis can lead to additional tissue damage,  increasing interleukin-1ß (IL-1ß) 
release, maladaptive scar formation, and adverse ventricular remodeling. All of which increase 
the risk of developing HF (Prabhu et al., 2017).  
 As a result, today inflammation as a pathogenic contributor to disease is a focus of 
research in many different fields involving diabetes mellitus (Goldfine & Shoelson, 2017), ALS 
(Meissner et al., 2010), cardiovascular disease (B. W. Van Tassell et al., 2017), and cancer 



























Figure 1: Inflammation post-acute myocardial infarction (Prabhu et al., 2017) 
1.2 The NLRP3 Inflammasome 
 The inflammasome, identified first in 2002 by Dr. Jurg Tschopp and colleagues 
(Martinon et al., 2002), is a macromolecular protein complex responsible for sensing danger 
signals, activating caspases, and pyroptotic release of pro-inflammatory cytokines initiating 
inflammatory signaling pathways (Swanson et al., 2019) (Toldo & Abbate, 2018).  
 Since Tchopp and colleagues’ groundbreaking work, other studies (Martinon et al., 2006) 





agonists of different types of inflammasomes named after the pattern-recognition receptor (PRR) 
regulating their activity (Lamkanfi & Dixit, 2014). Some of these inflammasomes include the 
NRLP1, NLRP3, NLRC4, and AIM2 inflammasomes. More importantly these findings from 
these initial studies have helped in detailing the role and delicate balance that inflammasomes 
help maintain during an innate immune inflammatory response. In particular when 
physiologically regulated, inflammasomes play an integral role in controlling innate immune 
pathways responsible for inflammation, host defense, and protection from injury and sepsis 
(Dagenais et al., 2012). Conversely, inflammasomes that are over-stimulated or not sufficiently 
suppressed can lead to exuberant inflammatory responses that are linked to many different 
inflammatory diseases (Dagenais et al., 2012).   
 Of all the inflammasomes that have been identified, the NLRP3 inflammasome is the one 
that has been most characterized (Toldo & Abbate, 2018). Similar to other inflammasomes, the 
NLRP3 inflammasome can aptly be described as a finely regulated macromolecular protein 
complex that activates a caspase -- caspase-1, and processes and releases pro-inflammatory 
cytokines such as IL-1ß and IL-18. Furthermore, what makes the NLRP3 inflammasome an 
important topic of research is the pathophysiological role it plays in acute to chronic 
inflammatory responses that contribute to many different inflammatory diseases, as well as its 
ability for sensing a wide variety of both intracellular danger and extracellular alarmin signals 
(Franchi et al., 2012). The following includes a list of common PAMPs and DAMPs (NLRP3 
agonists/stimuli): 
• DAMPs = MSU (monosodium urate) crystals, Ca++ influx, mROS  (mitochondrial 





hydroxyapatite crystal, silica, aluminum salts, asbestos, and fatty acids        
(Franchi et al., 2012) 
• PAMPs = pathogens that include viruses (influenza A), bacteria (LPS, Neisseria 
gonorrhoeae), gram-negative bacteria, and bacterial toxins like nigericin and 
maitotoxin. Broz and Dixit have suggested that low intracellular potassium 
concentrations that occurs from potassium release (K+ efflux) is associated with 
all NLRP3 activators, and thus may one day be proved to be sufficient enough on 
its own to trigger NLRP3 activation (Broz & Dixit, 2016) (Muñoz-Planillo et al., 
2013).   
 
 Additionally, these DAMPs/PAMPs are  
 
responsible for binding to and activating  
 
membrane-bound Toll-like receptors (TLRs).  
 
Once TLRs in the membrane are activated the  
 
resulting signal produced by DAMPs or  
 
PAMPs are transmitted into the cell and  
 
towards the nucleus as a downstream signal that  
 
is mediated by myeloid differentiation factor-88  
 
(MyD88) and interleukin-1 receptor-associated  
 
kinase -1, -4 (IRAK1/4) which will activate  
 
NF-𝜅B activity resulting in gene expression of  
 
the NLRP3 inflammasome components and  
 
proteins (Dagenais et al., 2012). 
       
  Figure 2: NLRP3 priming step (signal 1) and triggering 







The three NLRP3 (cryopyrin) inflammasome components produced are a sensor protein (NOD-
like receptor), adaptor protein (ASC), and an effector protein (caspase-1), which come together 
by way of homotypic pyrin domain (PYD-PYD) and caspase recruitment domain (CARD-
CARD) interactions (Lu et al., 2014). Before detailing the two-step process of activating and 
forming the NLRP3 inflammasome below is a brief summary detailing the components and 
proteins involved in regulating its formation.  
 
 The first component of the NLRP3 inflammasome serves as the sensing component 
which consists of NLRP3 itself. NLRP3 contains a leucine-rich repeat domain at the C-terminal, 
an NLR/NBD/NACHT domain at its center, and a 
pyrin domain at the N-terminal responsible for 
binding to the second component of this 
inflammasome (Martinon et al., 2006). 
 The second NLRP3 inflammasome component is 
the apoptosis speck-like protein containing a CARD 
(ASC) which serves as the adaptor protein. The 
adaptor protein ASC consists of a pyrin domain 
(PYD) and a caspase activation and recruitment 
domain (CARD). The function of ASC is to help 
recruit procaspase-1 for the purpose of associating ASC and procaspase-1 with NLRP3, thus 
bridging the sensor component (NLRs) with the downstream adaptor and effector (caspase-1) 
(Martinon et al., 2006). 





 The third component, caspase-1, is a cysteinyl aspartate-specific protease. Caspase-1 is 
initially produced as an inactive precursor pro-caspase-1. Pro-caspase-1 consists of a CARD, 
p20, and p10 subunits. After pro-caspase-1 is proteolytically cleaved, two p20 and two p10 
subunits will assemble into the active caspase-1, a heterotetramer that is responsible for cleaving 
pro-IL-1ß and pro-IL-18 to IL-1ß and IL-18 respectively and inducing pyroptosis, a cell death 
process that will be further described in a later section (Broz et al., 2010) 
 In addition to the three main components that form the NLRP3 inflammasome, there are 
other proteins such as Nek7, MARK4, and MAVs that have recently been investigated and 
suggested to regulate NLRP3 inflammasome formation and activation.  
 Nek7 is a serine-threonine kinase and member of the family of mammalian NIMA-related 
kinases (Neks) (De Souza et al., 2015) (He et al., 2016). According to research findings, Nek7 
contributes to mitotic spindle assembly during early mitosis by localizing to the centrosome to 
ensure mitotic progression (De Souza et al., 2015) (Schmid-Burgk et al., 2016). In addition, 
Nek7 is an NLRP3-binding protein that acts downstream of potassium efflux and is presumed to 
regulate the assembly and activation of the NLRP3 inflammasome (Schmid-Burgk et al., 2016). 
A study in 2016 showed that when Nek7 is absent, NLRP3 inflammasome response is blunted as 
evidenced by lower levels of caspase-1 and IL-1ß release. This study also showed that Nek7 only 
affects the NLRP3 inflammasome, thus displaying specificity in that no other inflammasomes 
(i.e. NLRC4 nor AIM2) showed marked effects by Nek7 binding (Schmid-Burgk et al., 2016)  
 Microtubule-affinity regulating kinase 4 (MARK4) is an evolutionarily conserved protein 
whose function is to regulate microtubule dynamics through phosphorylating microtubule 
associated proteins (MAP) (Trinczek et al., 2004). Additionally, Li et al. have shown that 





MARK4 regulates NLRP3 inflammasome activation is suggested to be by binding to NLRP3 and 
driving it to the microtubule-organizing center (MTOC), the site of NLRP3 inflammasome 
activation, via microtubule-based transport (Li et al., 2017).  
 Mitochondrial anti-viral signaling proteins (MAVS) is another protein that is presumed to 
associate with the NLRP3 inflammasomes and facilitate its oligomerization. A 2013 study 
showed that when knocking down MAVS expression in THP-1 and mouse macrophages, there 
was an attenuation of NLRP3 inflammasome activation. Furthermore, the study ultimately 
suggest that MAVS facilitates the recruitment of NLRP3 to the mitochondria and may enhance 
its oligomerization and activation by bringing it in close proximity to mROS (Park et al., 2013; 
Subramanian et al., 2013) 
 
1.2.1 NLRP3 Inflammasome Formation Pathway  
 The activation and formation of the NLRP3 inflammasome require two independent steps 
that are labeled as the priming and triggering steps. The main objective of the priming step is to 
induce the expression of NLPR3 inflammasome components via signaling pathways from the 
TLRs on the cell membrane and NF-𝜅B activation, thereby priming the cells to respond in the 
event of injury or pathogen exposure. Therefore, when extracellular primary signals, created by 
cellular debris or microbial products (DAMPs/PAMPs), bind to and stimulate Toll-like receptors 
(TLRs) located on the cell membrane, downstream signaling will activate the NF-𝜅B activity. 
NF-𝜅B (nuclear factor kappa-light-chain-enhancer of activated B cells) is a protein complex 
located in the cytoplasm that is capable of controlling cytokine production, and DNA 
transcription (i.e. gene expression) resulting in the translation and production of inflammasome 





Furthermore, as mentioned previously the downstream signaling that activates NF-𝜅B activity in 
the nucleus is mediated by MyD88 and IRAKs. Despite primary signals activating gene 
expression and formation of the individual NLRP3 components during the priming step, NLRP3 
inflammasome activation, oligomerization, and IL-1ß processing do not occur without a 
trigger/distress signal (Kelley et al., 2019).    
 According to experimental studies, one example of a trigger/distress signal capable of 
activating the NLRP3 inflammasome has been the production of mitochondrial reactive oxygen 
species (mROS) resulting from mitochondrial damage and oxidative stress (Muñoz-Planillo et 
al., 2013) (Dagenais et al., 2012). It has been suggested that mROS production not only induces 
NF-𝜅B-dependent gene expression seen in the priming step, but also NLRP3 inflammasome 
oligomerization that prepares the cell for inflammasome activation (Dagenais et al., 2012)  
 Another example of distress signals capable of activating the NLRP3 inflammasome is 
K+ efflux and cathepsin B release resulting from lysosomal destabilization. K+ efflux can also 
result from an increase in cell death that causes extracellular ATP (eATP), a byproduct of cell 
death, to attach to cells with P2X purinoreceptor 7 (P2X7) and induce inflammasome formation 
(Mezzaroma et al., 2011) (Franchi et al., 2012). Following the increase in K+ efflux and the 
resulting lowered K+ intracellular concentration, a cytosolic serine/threonine-protein kinase 
(Nek7) senses K+ efflux and subsequently regulates the oligomerization and recruitment of 
NLRP3 components (Schmid-Burgk et al., 2016).  
 Once the NLRP3 oligomerization process is induced, a circular structure is formed with a 
central core that becomes the site of ASC polymerization. Originating from this central core of 
polymerized ASC, a large number of pro-caspase-1 enzymes will be recruited, cleaved, and 





caspase-1 enzymes capable of enzymatically cleaving inactive pro-inflammatory cytokines pro-
IL-1ß and pro-IL-18 into active pro-inflammatory cytokines IL-1ß and IL-18 respectively. In 
addition, activated caspase-1 cleaves gasdermin D (GSDMD) which induces pyroptosis, a 
programmed cell death responsible for pore formation and the release of pro-inflammatory 
cytokines and intracellular/cytoplasmic content that further induces pro-inflammatory responses 








1.2.2 IL-1 Family Pro-inflammatory Cytokines Release Processes 
 Cytokines make up a large group of proteins that are released by cells of the immune 
system. Some examples of cytokines include chemokines, interferons, TNFs, and interleukins 
(ILs). The function and release of cytokines are important in mediating the signaling pathways 
involved in immunity and inflammation. To induce their effects on signaling pathways, 
cytokines can be released by a general conventional model, or a non-conventional model.  
 Through the general conventional model, which describes how most cytokines are 
secreted out of the cell, cytokines are first encoded and synthesized by genes that are inducible 
by inflammatory transcription factors (TFs) like NF-𝜅B, and AP-1 (Smale & Natoli, 2014). Once 
synthesized, cytokines that contain N-terminal secretion sequences will be able to insert into the 





endoplasmic reticulum (ER) in a co-translational manner (Lieberman et al., 2019). From the ER, 
cytokines will eventually be released into the extracellular space where they then bind to their 
appropriate receptors and promote inflammatory responses (Lieberman et al., 2019).  
 The other form of extracellular cytokine release, releases the most potent molecules of 
the innate immune system, the IL-1 family cytokines(i.e. IL-1⍺, IL-1ß, IL-18, and 8 other 
cytokines), through a process mediated by Gasdermin D (GSDMD), a pore-forming protein that 
consists of a C-terminus that auto-inhibits the pore-forming activity of its N-terminus (Kayagaki 
et al., 2015). Perhaps the most important cytokine released by this form of cytokine release is IL-
1ß, a pro-inflammatory cytokine that is initially formed as an inactive precursor. When activated 
IL-1ß functions not only as a potent pyrogen (a substance that produces fever) but also as an 
important signal that induces the synthesis and expression of several hundred downstream/ 
secondary inflammatory mediators (Dinarello, 2011). To induce these effects extracellular 
signals must first activate the NLRP3 inflammasome leading to autocatalytic activation of its 
effector -- caspase-1. Upon activation, caspase-1 proteolytically cleaves pro-IL-1ß, pro-IL-18, 
and Gasdermin D resulting in mature IL-1ß and IL-18 as well as Gasdermin-D’s N-terminal 
fragment that is now capable of forming pores within the cell membrane (Liu et al., 2016). In 
addition, caspase-1 is also known to cleave several proteins from the Krebs cycle which triggers 
a dramatic decrease in cell energy production resulting in cell swelling and rupture (Shao et al., 
2007). Consequently, the loss of cell membrane integrity resulting from the formation of a pore 
by GSDMD, cell swelling, and rupture of the membrane allows for the release of intracellular 
contents and pro-inflammatory cytokines into the extracellular space, a cell death process also 







1.3 The Role of the NLRP3 Inflammasome following Myocardial Injury 
 The role of cardiac inflammation, following myocardial injury, is to restore homeostasis 
by eliminating and removing offending agents (cell debris and dead cells/tissue) from the area of 
injury, which helps to bring about healing and wound repair by way of scar formation to the 
injured myocardium. However, several reports have now demonstrated that excessive 
inflammation modulated by the NLRP3 inflammasome, and IL-1ß processing has a role in 
pathophysiological processes that contribute to AMIs, cardiac remodeling, and compensatory 
mechanisms leading up to HF (Kawaguchi et al., 2011; Mezzaroma et al., 2011; B. W. Van 
Tassell, Toldo, et al., 2013).  
 Beginning with the response to necrotic and apoptotic cell death that occurs during an 
acute myocardial infarction; studies show that the innate immune system utilizes inflammatory 
inducers (DAMPs released from necrotic cells: eATP, K+ efflux etc.), membrane sensors (PRRs: 
TLRs), cytosolic sensors (NLRP3 inflammasomes), and cytokine release (IL-1ß, IL-6, IL-18) to 
initiate enhanced inflammatory responses (Land, 2015). Responses, that cause local surges of 
pro-inflammatory cytokines to significantly amplify/exacerbate sterile inflammatory responses 
by inducing chemotactic recruitment of immune cells (neutrophils, macrophages, and fibroblasts) 
to the infarcted myocardium, and activating the NLRP3 inflammasomes in leukocytes and 
cardiac resident cells. Consequently, an enhanced inflammatory response, modulated by NLRP3 
inflammasome, leads to increased inflammatory cell death (pyroptosis), additional loss of 
functional myocardium, further dysregulation in recovery processes (fibrotic non-functional scar 
formation) and systolic dysfunction that can persist and lead to systemic inflammation seen AMI, 





 The potential of limiting/attenuating the inflammatory response to help in cardiovascular 
diseases has led to early experimental studies investigating broad anti-inflammatory 
interventions using glucocorticoids (Metz et al., 1986) and NSAIDS (Kalkman et al., 1995) and 
later targeted anti-inflammatory interventions that targeted cytokines, CRP, and NLRP3, some of 
which are discussed and referenced in a later section. Thanks to what was learned from these 
studies, many current studies have developed new pharmacological drugs to target the NLRP3 
inflammasome and its end products (IL-1ß and IL-18) with the goal of determining the efficacy 
that targeted anti-inflammatory interventions could have on decreasing cell death, limiting LV 
enlargement after an AMI, and overall reducing the risk/incidence of heart failure (Mezzaroma et 
al., 2011) (B. W. Van Tassell et al., 2017) 
 
1.4 Goal of the Study   
 When applied in a timely manner, reperfusion strategies in the form of percutaneous 
coronary interventions (PCI), anti-thrombolytic medications, and implantation of stents, have 
drastically improved survival rates and overall prognosis of AMI patients. However, there are 
still a number of patients that do not receive reperfusion treatment during the appropriate 
therapeutic window of time, as well as patients with comorbidities such as diabetes, obesity, 
advanced age, hypertension, and large infarct sizes, that overall impair the efficacy of GDMT 
and significantly increases the risk of developing further myocardial injury, adverse ventricular 
remodeling, and heart failure.  
 In order to address these concerns, multiple experimental studies along with this present 





modulated inflammatory signals that promote further myocardial injury in cardiovascular 
diseases.  
 In contrast to studies investigating the anti-inflammatory effects of targeting downstream 
NLRP3 mediators of inflammation (IL-1 receptors, IL-1ß, IL-6), this present study was designed 
to utilize OLT1177 (dapansutrile), a recently developed NLRP3 inhibitor, to target and inhibit 
the upstream NLRP3 formation process thereby resulting in less caspase-1 being activated, less 
IL-1ß produced, and overall a decreased sterile inflammatory response. Furthermore, evidence-
based research from a previous study suggests that OLT1177, when given promptly to mice 
following ischemia-reperfusion injury from a transiently ligated AMI, was capable of reducing 
infarct size and caspase-1 activity, as well as preserving cardiac systolic function thus confirming 
the potential clinical translational value of utilizing OLT1177 as a cardioprotective strategy after 
myocardial injury (Toldo et al., 2019). Additionally, previous studies have shown that chronic 
IL-1ß activity promotes adverse cardiac remodeling, and that  IL-1ß inhibition given in the 
chronic phase of post-AMI remodeling, improves ventricular remodeling and ß-adrenergic 
responsiveness as well as reduces ventricular filling pressures (Mezzaroma et al., 2011)  
 Hence, we hypothesize that by administering OLT1177 to inhibit the NLRP3 
inflammasome after a myocardial injury we will not only prevent the NLRP3 inflammasome 
from promoting aberrant inflammasome signaling production, but also mitigate the inflammatory 
response, thereby improving cardiac remodeling and limiting heart failure. To evaluate this 
hypothesis, we examined the effects of OLT1177 throughout a 10-week time period in mice 





 1. Measuring the physiological benefit that OLT1177 has on ejection fraction, and 
 cardiac remodeling through the use of transthoracic echocardiography (TTE) 
 evaluation. 
 2. Measuring the effects of OLT1177 on preserving the heart’s contractile reserve and ß-
 adrenergic responsiveness through the use of isoproterenol challenge and TTE 
 evaluation. 
 3. Assessing the physiological benefits that OLT1177 has on limiting systolic and 
 diastolic dysfunction through the use of LV catheterization (measuring LVEDP, +dP/dT, 
 -dP/dT, and peak systolic pressure). 
Currently, there are no selective NLRP3 inhibitors that are clinically available at this time, thus it 
is our aim that the knowledge gained from this research will bring us one step closer to finding 
safe and effective ways to use a novel therapeutic class of NLRP3 inflammasome inhibitors to 
slow adverse LV remodeling and improve clinical outcomes.  
 
1.5 OLT1177 Therapy   
 
 OLT1177 (dapansutrile) is a ß-sulfonyl  
 
nitrile molecule designed to inhibit the NLRP3  
 
inflammasome’s capability of producing IL-1ß and 
IL-18 inflammatory cytokines. A previous study by  Marchetti and colleagues described the 
specificity of OLT1177, by demonstrating that it had no effect on other inflammasome types 
such as AIM2 nor NLRC4 inflammasomes (Marchetti, Swartzwelter, Gamboni, et al., 2018b). 
Additional findings from this study have shown that OLT1177 is safe in humans, therefore its 





unique inhibitory effect on the NLRP3 inflammasome has been a topic of research since its 
development in 2017 due to its potential for treatment of IL-1ß- and IL-18-mediated diseases.   
 
1.5.1 Routes of Administration  
 OLT1177’s routes of administration used in previous and current studies include the 
following: oral route (enriched diet and capsule form), injection route (intraperitoneal), and oral 
gavage. For oral OLT1177 administration, OLT1177-enriched diet (3.75g OLT1177 per kg of 
food or 4.5g OLT1177 per kg of food) has been used in previous murine studies (Marchetti, 
Swartzwelter, Gamboni, et al., 2018a; Toldo et al., 2019) while oral OTL1177 capsules used in 
phase I-II clinical trials are currently being investigated in human heart failure patients (clinical 
trial identifier: NCT03534297)  
 In regards to the injection route of administration, OLT1177 injections into the peritoneal 
cavity (i.p. injections), have been primarily used in murine studies by first solubilizing crystalline 
OLT1177 with sterile saline and subsequently injecting OLT117 using the following doses in 
mice: 6, 60, 100 or 600 mg/kg OLT1177 i.p. dose (Toldo et al., 2019), or 200mg/kg OLT1177 
i.p. (Sánchez-Fernández et al., 2019). Similarly, oral gavage of OLT1177 involves solubilizing a 
dosage of OLT1177 (60, 600mg/kg) but instead of using saline, it is solubilized with distilled 
water and subsequently administered to mice (Marchetti, Swartzwelter, Koenders, et al., 2018). 
 
1.5.2 OLT1177 Effects and Mechanism of Action 
 Much of what is known regarding the effects and mechanism of action of OLT1177 





their results from a phase 1 clinical trial that involved 35 healthy human subjects. Overall, the 
results from this clinical trial and pharmacokinetic studies demonstrated that OLT1177 at 
different dosages (100, 300, and 1000mg capsules): has a long half-life (approx. 23 hrs.), is safe 
(showing no organ toxicities) and well tolerated. This report also contained the results from in 
vitro, in vivo, and whole cell-patch clamp studies.  
 From in vitro studies on human blood-derived macrophages (MBDM), murine 
macrophage cell line, and freshly isolated human blood neutrophils, results demonstrated that 
OLT1177: specifically targets the NLRP3 inflammasome, prevents NLRP3 inflammasome 
formation by inhibiting ATPase activity, suppresses caspase-1 activity and IL-1ß and IL-18 
release, and has no effect on TNFα and on the priming step of NLRP3 formation. Furthermore, 
evidence that OLT1177 prevents NLRP3 inflammasome formation was provided through the use 
of immunoprecipitation and FRET analysis on J774A.1 cells. The results from this experiment 
demonstrated that OLT1177 prevents NLRP3 oligomerization and activation by directly 
inhibiting NLRP3 inflammasome’s ATPase activity necessary for the recruitment and 
association of NLRP3-ASC and NLRP3-caspase-1 (Duncan et al., 2007). Without these domain 
associations, NLRP3 oligomerization is inhibited leading to a reduction in caspase-1 activity, the 
release of mature inflammatory cytokines (IL-1ß and IL-18), as well as in pyroptotic cell death. 
 The results from in vivo studies on mice that had undergone LPS-induced systemic 
inflammation, demonstrated that OLT1177 reduces the severity of systemic inflammation as 
evidenced by decreased levels of chemokines and cytokines in lung, liver, spleen, and skeletal 
muscle tissues. In addition, results from in vivo studies demonstrated that OLT1177 increases 
oxidative metabolism. By way of examining excised muscle tissue, OLT-treated mice displayed 





improved glutathione homeostasis that is important in antioxidant effects and in oxidative 
metabolism. 
 Lastly, the report described utilizing whole-cell patch-clamp technique on human-LPS 
primed monocytic U937 cells treated with OLT1177 and found that OLT1177 does not inhibit 
the K+ ion current change (K+ efflux), a common activator of the NLRP3 inflammasome. As 
mentioned earlier, activation of P2X7 receptor by eATP (a byproduct of cell death) results in K+ 
efflux from the cell as well as an expected current change to identify while utilizing the whole-
cell patch-clamp technique. Consequently, the results from the patch-clamp study led the 
investigators to conclude that OLT1177 must inhibit the NLRP3 inflammasome by a mechanism 































CHAPTER 2: Methods and Materials 
 
2.1 Ethical Approval 
 All experimental procedures in this study were performed in accordance with the “Guide 
for the Care and Use of Laboratory Animals” published by the National Institutes of Health (8th 
ed. revised 2011). The study protocol was approved by the Virginia Commonwealth University 
Institutional Animal Care and Use Committee.       
 
2.2 Study Design 
 The main variables that this study tested for in mice with a nonreperfused AMI, are the 
changes in a 10-week time period that occur to cardiac function (systolic and diastolic function) 
LV cardiac remodeling, and contractile reserve. 
 In this present study 60 adult male Imprinting Control Region (ICR) mice (8 weeks old) 
of 35-45g of weight, supplied by Envigo (Indianapolis, IN) underwent an open-heart surgical 
procedure. Of these, 54 mice underwent an experimental AMI via permanent ligation of the left 
coronary artery near its origin (proximal), while the remaining 6 mice underwent a sham 
operation procedure. Three days after inducing the experimental AMI or sham procedure, the 
infarct size and cardiac remodeling of the surviving mice (n=35, 58%)  were assessed non-
invasively via transthoracic echocardiogram (TTE). Based on these echocardiogram values, mice 
were assigned, utilizing this study’s inclusion criteria and comparative analysis, into 1 of 4 
groups each with 1 of 3 different diets to eat from for 10 weeks. These 3 different diets were 





(Groups 3 and 4). Furthermore, all three diets were provided by Research Diets, Inc (New 
Brunswick, NJ) and administered to mice 1 week after experimental AMI surgery, and 
repeatedly added throughout the duration of this 10-week study. 
 At 4-weeks and 10-weeks, all surviving mice (n=28, 47%) underwent a transthoracic 
echocardiogram along with an isoproterenol challenge to test the heart’s contractile reserve.  
At the end of 10 weeks, 2 of 10 mice (20%) mice had died in the OLT 3.75 gr/kg group, as 
compared with 2 of 9 mice (22%) in the OLT 7.5 gr/kg group, 3 of 10 mice (30%) in the 
standard diet group, and 0 of 6 (0%) in the sham-operated group. 
 Lastly, the mice underwent an invasive LV catheterization procedure and then euthanized 
by pentobarbital overdose. The hearts were then explanted, along with plasma and stored in a 
freezer (-80C) for future ELISA analysis.    
 
2.2.1 Experimental AMI Model Procedure 
 The experimental AMI model used in this study was performed under sterile conditions 
and involved permanently ligating the left anterior descending coronary artery near its origin. For 
the purpose of our study, this nonreperfused AMI model was utilized to simulate the drastic 
changes that occur following a myocardial injury such as adverse cardiac remodeling in the form 
of ischemic dilated cardiomyopathy and LV hypertrophy. To accomplish this complex, invasive, 
and high-risk surgery, a skilled investigator performed these surgical procedures utilizing the 
following protocol.  
 Each mouse was anesthetized intraperitoneally with the injection of sodium pentobarbital 
(50-70mg/kg) and subsequently shaved in the left chest area. Next, the mouse was placed and 





mice were connected to a positive-pressure ventilator. The tidal volume of this ventilator was set 
at 0.25ml, and the respiratory rate was adjusted to 133cycles/min. A left thoracotomy (a surgical 
procedure allowing access to the thoracic organs: heart and lungs) was performed in the 4th 
intercostal space. The right lateral decubitus position also allowed access for a pericardiectomy 
(surgical removal of part or most of the pericardium). Once the heart was exposed, the left 
anterior descending coronary artery was identified and permanently occluded with the use of a 7-
0 silk suture tied around the coronary artery. After each coronary artery occlusion, the thoracic 
cavity was closed with sutures and the mice were extubated. The mice were then left to recover 
on heating pads and slow-release buprenorphine (1mg/kg) was administered. Once recovered, 
the mice were housed under climate-controlled conditions at a 12-hr light/dark cycle and 
provided with standard mice chow/food and water for the next 7 days, wherein afterward their 
diet was changed to either standard diet or diet containing low- or high-dose OLT1177. 
Furthermore, the mice that survived the experimental AMI procedure showed exceptional 
resilience in the form of eating, drinking, and moving around in their cages normally, and 
without much discomfort. 
 In total 54 mice underwent the experimental permanent ligation AMI, while the 
remaining 6 mice underwent a sham operation procedure that included every step in the protocol 
except the left coronary artery ligation. A summary of the mortality rate in mice after the AMI 










Table 1: The mortality, survival, and incidence of infarction before setting up 
experimental groups 
Attempted open heart surgeries.......................................................60 
Survival of open-heart surgery + 3d ECHO...................................35 of 60 (58%) 
Attempted AMI permanent occlusions...........................................54 of 60 (90%) 
Initial Incidence of infarction (successful occlusions)................... 29 of 54 (54%)   
Unsuccessful occlusion (i.e. LMI).................................................1 of 54 (0.02%) 
Operative deaths (during AMI or ECHO)......................................11 of 60 (18%) 
Late deaths (~1-3d after ECHO).....................................................13 of 60 (22%)            
 Note: the mice that died in the post-operative period or had unsuccessful occlusions 




2.2.2 Test Subject and Inclusion Criteria 
 Three days (72 hrs.) after AMI surgery, the surviving mice (n=35, 58%) underwent 
transthoracic echocardiography (TTE). In our present study, TTE was performed three times 
throughout 10 weeks to assess cardiac function, infarct size, and cardiac remodeling in a non-
invasive manner. The results from the initial TTE were particularly important in allowing us to 
assess and determine which mice would be part of the study and also set up different groups 
based on our inclusion criteria and exclusion criteria.  
 The inclusion criteria of this study consisted of the following: mice with a large 
nonreperfused anterior infarct (> 4 akinetic segments involving the anterior wall), an enlarged 
ventricle (left ventricular end-diastolic diameter [LVEDD] > 4.4mm), and systolic dysfunction 





did not meet the inclusion criteria such as mice with a lateral myocardial infarction (LMI), mice 
that underwent a sham operation, and mice that did not survive the AMI procedure. 
 
2.2.3 Selection of Control and Experimental groups 
 After the assessment of the initial 3-day ECHO values, these mice were assigned to four 
different groups by an investigator not involved in the assessment of endpoints. Below is a 
description of the four groups and the number of mice that survived the full 10 weeks. Note: 
these are the mice whose ECHO and LV catheterization values were utilized for this study’s 
results, tables, and figures. 
 At the end of 10 weeks, all sham-operated mice (n=6), and 41% of the mice (n=22) that 
had undergone the experimental AMI were alive. Whereas 59% of the mice (n=32) that 
underwent the experimental AMI had died: during the initial AMI procedure (n=11), shortly after 
echocardiogram(s) (n= 13), or throughout the 10 weeks due to causes linked to the change in diet 
(from regular chow to the experimental OLT diet) (n=1), or not surviving anesthesia during 
week-4 and week-10 echocardiogram assessments (n=4). Furthermore, two of the mice were 
euthanized due to succumbing to fighting wounds (n=1), or illness (n=1), and one mouse (n=1) 
was excluded for having an LMI.  
• Group 1 consisted of 10 mice that underwent an AMI procedure. The diet that these mice 
received for 10 weeks was a diet containing OLT1177 (3.75 gr/kg). This diet was also 
referred to as the low-dose OLT diet and was gray in color.  
• Group 2 consisted of 9 mice that underwent an AMI procedure. The diet that these mice 
received for 10 weeks was a diet containing OLT1177 (7.50 gr/kg). This diet was also 





• Group 3 consisted of 10 mice that underwent an AMI procedure. The diet that these mice 
received for 10 weeks was the control/standard diet. This diet contained no OLT1177 and 
was green in color. 
• Group 4 consisted of 6 mice that underwent a sham operation. The diet that these mice 
received for 10 weeks was the control/standard diet. This diet contained no OLT1177 and 
was green in color.  
   
2.2.4 Treatment with OLT1177 Diet  
 The experimental treatment tested in this study was OLT1177, a pharmacological NLRP3 
inflammasome inhibitor, that was supplemented/admixed into mice chow (0.5” pellets) and 
color-coded by Research Diets, Inc (New Brunswick, NJ). This diet, which was supplemented 
with either low- or high-dose OLT1177 (3.75g or 7.50g of OLT1177 per kg of food), was 
administered 1-week post-AMI to experimental Groups 1 and 2 respectively. Research Diets, Inc 
(New Brunswick, NJ) also provided the control diet which was labeled as standard/control diet. 
This control diet did not contain OLT1177 and was administered to Group 3 (control group 
mice) and Group 4 (sham-operated mice) 
 Throughout the remainder of this 10-week study, the survival of the animals and the 
average food consumption of every cage was assessed and recorded every ~1-3 days. To ensure 
the mice were eating sufficiently, food was added regularly, and further monitoring was done by 
weighing and recording the weight of each mouse once a week for 10 weeks. In addition, all 
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Figure 6: Average weekly food consumption of all four groups during the 10-week study 
 
 


























 As can be seen in Figures 6 and 7, during the first 2-3 weeks of the study, both OLT-
treated mice groups consumed considerably lower amounts of their diet, especially the high-dose 
OLT-treated group. Consequently, the high-dose OLT-treated group (Group 2) also had lower 
weights than other mice groups. One possible reason for this difference in food consumption and 
body weight can be due to a period of acclimation to a new diet, with preferences of flavors 
playing a possible role. Nevertheless, food consumption and body weight of Group 2 mice 
gradually increased to comparable levels of the other mice groups in the study.    
 
2.3 Transthoracic Echocardiography (TTE) 
 Transthoracic echocardiography is a noninvasive imaging technique that allows one to 
monitor and visualize in real-time the heart’s morphology, infarct size, and function. To produce 
images, echocardiography utilizes a piezoelectric crystal contained within a transducer to emit a 
controlled high-frequency sound (ultrasound) waves that have the capability to travel through 
any medium (Mohamed et al., 2010).  This transducer is also responsible for detecting ultrasound 
waves/echoes that are reflected back to the transducer from body tissues and converted into 
electrical signals and images appearing on the echocardiography system screen. These echo 
signals that are reflected from different body tissues differ in brightness depending on the density 
of that particular body tissue. For example, dense tissues like pericardium will appear 
white/bright, whereas hollow tissues like blood-filled chambers of the heart will appear black, 
signifying that no echo signals were produced/reflected. 
 In this present study we utilized echocardiography to assess and monitor the changes and 
dissimilarities in LV systolic function, infarct size, cardiac remodeling, and wall motion 





OLT1177) and mice eating the standard diet. In addition to the 3-day echocardiography, TTE 
was also performed at 4-weeks and 10-weeks post-AMI. The echocardiography system that was 
used in this study was the Vevo770 High Resolution in vivo micro-imaging system 
(VisualSonics Inc, Toronto, Ontario) along with a transducer probe with a high transmit 
frequency of 30-MHz (Respress & Wehrens, 2010). Note: for comparison, the typical range of 
frequencies used in adult human echocardiography ranges from 2.0 to 5.0 MHz (Mitchell et al., 
2019) 
 On days when transthoracic echocardiography was performed, each mouse was mildly 
anesthetized with pentobarbital (30-50 mg/kg) and shaved at the upper and lower chest area. 
Following this, the mouse was secured and placed in a supine position on a warmed VEVO770 
platform. While in the supine position the investigator, that performed and read all 
echocardiograms, applied warmed ultrasound transmission gel on the animal’s chest to enhance 
TTE image quality and next placed the transducer on the thoracic region to visualize the heart 
from the parasternal short-axis view (Note: this investigator was blinded to treatment allocation). 
 While echocardiography has three different imaging modes (B-mode, M-mode, and 
Doppler tissue imaging), for this study the animal’s hearts were visualized using B-mode (2-D 
imaging). When the transducer was appropriately placed to see the parasternal short-axis (PSAX) 
view, B-mode reliably produced grayscale maps/images of the heart that allowed us to visualize 
ventricular wall motion abnormalities associated with infarcted myocardium (Lilly, 2013) and 
estimate the size of the left ventricle (Mitchell et al., 2019). Estimating the size of the LV is 
especially useful in assessing LV systolic function and cardiac enlargement (dilatation), thereby 
allowing researchers and clinicians a way to monitor pathophysiologies and responses to 





parameters that were evaluated were the left ventricular end-diastolic diameter (LVEDD) and left 
ventricular end-systolic diameter (LVESD).  
 The manner in which infarct size and regional myocardial function were visually assessed 
was by evaluating the regional wall motion and left ventricular (LV) wall thickening through the 
usage of the 16-segment model of the left ventricle (LV) that allowed us to assess LV wall 
motion and wall thickening (Pellikka et al., 2020). While other segmentation models are used 
clinically, like the 17-segment and 18-segment models, we utilized the 16-segment model which 
was recommended for studies assessing wall motion and not segments located at the tip of the 
apex, whose wall would be imperceptible in our studies and thus irrelevant (R. Lang, L. Badano, 
V. Mor-Avi, J. Afilalo, A. Armstrong, 2015).  
 Through this 16-segment model, the investigator individually counted, analyzed, and 
graded the function of the 16-segments of the LV, giving a score of either 3 or 4 according to a 
4-grade scoring system. This is especially useful when making visual assessments of LV 
myocardial regions that are supplied by occluded coronary arteries and identified by the 
reduction in motion (hypokinesis) or lack thereof (akinesis) in an ischemic, infarcted, or scarred 
myocardial wall region (R. Lang, L. Badano, V. Mor-Avi, J. Afilalo, A. Armstrong, 2015). The 
grades from this 16-segment model are described in Table 2. By averaging the scores of all 
segments visualized, a wall motion score index was produced and used to estimate the size of the 



















 Table 2: The 4-grade scoring system utilized alongside the 16-segment model.   
  (Pellikka et al., 2020). 
 
 During these LV wall thickening readings, an investigator also utilized a cursor on the 
echo system screen to mark the location of the endocardial border during diastole and assess the 
change that occurs to LV wall thickening during systole, which helped in estimating the 
thickness of the LV wall. (Pellikka et al., 2020). From these images and M-mode tracing 
(Doppler data), the parameters that were evaluated included anterior wall diastolic thickness 
(AWDT), posterior wall diastolic thickness (PWDT), anterior wall systolic thickness (AWST), 
and posterior wall systolic thickness (PWST). 
 The left ventricular structural parameters that were visually assessed with the use of TTE 
were also utilized to calculate left ventricular fractional shortening (FS), ejection fraction (EF), 
and LV mass.  
 LV fractional shortening is a calculated parameter that measures the functional capacity 
that the heart is able to squeeze/contract. It was calculated utilizing the following formula:  
   LVFS = (LVEDD-LVESD) / LVEDD x 100 
 LV Ejection fraction is a measure of contractile function and it was calculated with the 
Teichholz formula. To measure the left ventricular ejection fraction, the measured LV end-
diastolic and end-systolic areas were measured with B-mode TTE and converted to volumes 
LVESV and LVEDV. With these values the following formula is capable of calculating LVEF:  
Score Wall Motion Endocardial Motion 
Systolic Increase in 
Thickness 
1 Normal Normal >50% 
2 Hypokinetic Reduced <40% 
3 Akinetic Absent <10% 





   LVEF = (EDV – ESV) / EDV x 100 
However, when it comes to changes in shape from a physiologically ellipsoid to an adverse 
dilated shape, the LVEF was derived utilizing the Teicholz formula, a formula dependent on 
estimating LV end-systolic and end-diastolic volumes to the third power of the diameter 
multiplied by a factor of 1.047 according to the ellipsoid shape in which the length is twice the 
diameter: (Toldo et al., 2019). 
   LVEF = [LVEDD^3 – LVESD^3] / LVEDD^3    
 LV mass is a strong predictor of cardiovascular events that is also calculated utilizing M-
mode echocardiography parameters. Although there are several methods that can calculate the 
LV mass, the method that was utilized in this study was the Linear Method. Through the Linear 
Method, LV mass was calculated utilizing the Cube Formula, a geometric formula that 
incorporates the 2D echocardiography linear measurements of LV diastolic diameter and wall 
thickness to first calculate the volume of the LV myocardium. Then it converts the volume to 
mass by multiplying the volume of LV myocardium by the myocardial density (approx.1.05 
g/mL in humans)(R. Lang, L. Badano, V. Mor-Avi, J. Afilalo, A. Armstrong, 2015) 
  LV mass = 0.8 ⋅ 1.04 ⋅ [(IVS + LVID + PWT)^3 – LVID^3] + 0.6g 
Note: IVS, interventricular septum; LVID, left ventricle internal diameter; PWT, inferolateral 
wall thickness.  
2.4 Isoproterenol Challenge 
 Immediately following the 4-week and 10-week echocardiogram, isoproterenol (20 
ng/mouse) was injected intraperitoneally to each anesthetized mouse while in the supine position 





 Furthermore, at this point in the 10-week study all mice that underwent a permanent 
ligated nonreperfused AMI would have also experienced adverse cardiac remodeling leading to 
heart failure. As mentioned previously, cardiac remodeling is regulated by neurohormonal, 
RAAS, and inflammatory signaling pathways, that are initially beneficial, but as time passes 
becomes maladaptive leading to adverse ventricular remodeling and heart failure. Additionally, 
as cardiac efficiency diminishes significant desensitization and downregulation of ß-adrenergic 
receptors occurs leading to reduced responsiveness of the ß-adrenergic receptor system and loss 
of contractility (Lohse et al., 2003). 
 Isoproterenol is a potent, synthetic β-adrenergic receptor agonist that has positive 
chronotropic (increased HR) and inotropic (increased contractility) properties. As a result, we 
utilized isoproterenol to characterize OLT1177’s effect on preserving systolic function, 
contractile reserve, and ß-adrenergic sympathetic responses in OLT-treated mice. Through the 
use of TTE, measurements were taken to calculate the percent increase in EF (contractile 
reserve) and LVFS within 5 minutes after isoproterenol injection.   
 
2.5 LV Catheterization Procedure 
 Eight days after the 10-week TTE, all surviving mice underwent LV catheterization, a 
terminal procedure that was utilized to evaluate LV function in vivo.    
 In preparation for this procedure, all mice were anesthetized with pentobarbital (50-70 
mg/kg) and shaved at the anterior neck region. After the preparation of the mice and surgical 
environment, incisions were made in the neck area of each mouse. These incisions exposed the 
vasculature of the neck area particularly the carotid arteries. Next, a pressure probe catheter 
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was inserted into the right carotid artery and was further driven to the left ventricle of the heart to 
measure intracardiac pressure-volume tracings. Additionally, when a catheter is inserted into a 
blood vessel leading to the heart, each cardiac chamber produces a characteristic pressure-
volume loop that is important in both locating the position of the probe catheter, as well as 
deriving important in vivo physiologic information. Although the probe catheter is small, it was 
extremely intricate and helpful in allowing us to measure and record the Peak systolic pressures 
(PSP), LV end-diastolic pressures (LVEDP), and velocity of contraction and relaxation (+dP/dt 
and -dP/dt). Furthermore, the values from this probe catheter were recorded (in real-time) and 
measured using Labchart Pro 5 (Millar Inc., Houston, TX).  
 
















   
 
Figure 8: Timeline of the study protocol. LAD, Left anterior descending artery; SD, standard   







2.7 Statistical Analysis  
 All data presented in the following chapter utilized values derived from the procedures 
and techniques explained in this chapter. Additionally, the values from these procedures and 
techniques are presented as the mean and standard error of the mean. The differences between 
mouse treatment groups were compared by utilizing two-tailed Student’s T-test. One-way 
analysis of variance (ANOVA) was used for the comparison of two different doses and the 
control condition with post-hoc Bonferroni’s test for multiple comparisons. Unadjusted p-values 




















CHAPTER 3: Results 
  
3.1 The Effects of OLT1177 on Systolic Function 
 The left ventricular ejection fraction (LVEF) of all surviving mice were measured 3 days, 
4-weeks, and 10-weeks post-AMI through the use of transthoracic echocardiography (TTE).  
From these TTE measurements measuring LVEF at 3-days post-AMI (Figure 9), we see a 
marked decrease in systolic function, as evidenced by the low mean LVEF (27.6  0.9%) and 
LVFS (12.9  0.4%) of all mice groups that underwent permanent ligation of the left anterior 
descending coronary artery (Table 3, 4, and 5). Whereas the mice group that underwent the sham 
operation maintained normal ejection fractions (64.3  2.1%) and LV fractional shortening (34.8 
 1.6%). After the assessment of the initial 3-day ECHO values, these mice were assigned to 
four different groups. 
 Based on TTE measurement comparisons at 3-days and at 10-weeks post-AMI (Figure 9) 
no significant differences in LVEF were noted between the OLT-treated mice groups and the 
control diet mice group. Additionally, both low- and high-dose OLT-treated experimental groups 
showed similar ejection fractions and downward trends in LVEF when compared to the control 
group (22.6  1.8% in OLT 3.75gr/kg or 24.7  3.1% in OLT 7.50gr/kg vs 21.9  1.9% in 
control group, P = 0.77, P = 0.44)  (Figure 10). Therefore, these data indicate that OLT1177 had 











































OLT 3.75 gr/kg (N=8)
OLT 7.50 gr/kg (N=7) 3 days 10 weeks
***
* p<0.0005 vs sham
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Figure 9: LVEF, Left ventricular ejection fraction at 3-days and 10-weeks after permanent ligation of      






























































OLT 3.75 gr/kg (N=8)
OLT 7.50 gr/kg (N=7)
3 days 10 weeks
* p<0.005 vs sham







LVEDD at 3 days and 10 weeks post-AMI
3.2 The Effects of OLT1177 on Cardiac Remodeling 
 As expected, TTE measurements acquired at 3-days post-AMI show pronounced cardiac 
remodeling in the form of LV dilatation and eccentric LV hypertrophy, as evidenced by the 
significant increase in LVEDD, LVESD, and LV mass in all mice that underwent permanent 
ligation of the left anterior descending coronary artery (Figure 11, 13, 15). Whereas sham- 
operated mice, when compared to treatment and control groups displayed a significantly 
preserved LVEDD, LVESD, and LV mass, thus no cardiac remodeling.  
LVEDD: 
TTE parameters measured throughout the 10-week study show that both OLT-treated mice 
groups and control group mice, when compared to the sham group, had significant increases in 
LVEDD after 10 weeks: control group mice (6.38  0.26mm vs 4.07  0.10mm, P < 0.0005), low 
dose OLT group mice (5.71  0.16 vs 4.07  0.10mm, P < 0.0005), and high dose OLT group 



















Figure 11: LVEDD, Left ventricular end diastolic diameter at 3-days and 10-weeks after permanent  























LVEDD at 3 days, 4 weeks, & 10 weeks post-AMI
Sham (N=6)
Control diet (N=7)
OLT 3.75 gr/kg (N=8)
OLT 7.50 gr/kg (N=7)







Additionally, both low- and high-dose OLT-treated experimental groups displayed a similar 
upward trend in LVEDD when compared to the control group (Figure 12). LVEDD TTE 
measurements after 10 weeks suggests that both OLT-treated mice groups, when compared to the 

























TTE parameters measured at 3 days and 10 weeks after permanent ligation surgery show that 
both OLT-treated mice groups and control diet group mice had similar and significant percent 
increases in LVESD: control group mice (+33%, P < 0.0005), low dose OLT group mice (+30%, 
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* p<0.005 vs sham

























LVESD at 3 days, 4 weeks, & 10 weeks post-AMI
Sham (N=6)
Control diet (N=7)
OLT 3.75 gr/kg (N=8)
OLT 7.50 gr/kg (N=7)



























Figure 13: LVESD, Left ventricular end systolic diameter at 3-days and 10-weeks after permanent  





















Figure 14: LVESD, Left ventricular end systolic diameter at 3-days, 4-weeks, and 10-weeks after 






LVESD TTE measurement after 10 weeks also demonstrated that neither low dose OLT-treated 
mice (3.75gr/kg OLT), nor high dose OLT-treated mice (7.50gr/kg) had a significant effect on 
attenuating ventricular enlargement in relation to LVESD when compared to the control group 
(5.21   0.12mm in OLT 3.75gr/kg or 5.42  0.28mm in OLT 7.5 gr/kg vs 5.62   0.24mm 
control group,  P = 0.13 and P = 0.58 respectively) (Figure 13, 14). 
 
Calculated LV Mass: 
TTE measurements also allowed us to utilize ECHO values to calculate left ventricular mass.  
TTE parameters measured at 3 days post-AMI (Figure 15) show that both OLT-treated mice 
groups and control diet group mice, when compared to ECHO values measured at 10 weeks post-
AMI, had significant increase in LV mass: control group mice (110.5  6.0mg vs 187.1  
13.5mg, P < 0.05), low dose OLT group mice (104.4  3.4mg vs 157.5   12.1mg , P < 0.05), 
and high dose OLT group mice (96.5  6.3 vs 180.4  17.5mg, P < 0.05). Similarly, from Figure 
16, we see that the high-dose OLT-treated mice group and the control diet group show a similar 
upward trend in LV mass throughout the 10-week study. Figure 16 also appears to show a 
somewhat attenuated LV mass in low-dose OLT-treated mice, however this finding was not 
significant when compared to the control group. 
 All things considered, Figure 15 shows that when comparing both OLT-treated mice 
groups to the control group, OLT1177 had no significant effect on attenuating the gradual 
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LV Mass at 3 days, 4 weeks, & 10 weeks post-AMI






















Figure 15: Calculated LV Mass at 3-days and 10-weeks after permanent ligation of the left anterior 




















Figure 16: Calculated LV Mass at 3-days, 4-weeks and 10-weeks after permanent ligation surgery 
 
 The significant increase in LV mass of all mice groups that underwent nonreperfused 
AMI surgery, indicates that cardiac remodeling in the form of LV hypertrophy has occurred 
(Figure 15 and 16). To determine whether concentric or eccentric LV hypertrophy occurred, TTE 





Based on these ECHO values, we determined that both OLT-treated mice groups and the control 
diet group underwent eccentric LV hypertrophy, as evidenced by the increase in LV mass along 
with an increase in diameters (LVEDD, LVESD) seen in Tables 3, 4, and 5. The increase in the 
diameter or cavity of the left ventricle, as previously discussed, initially allows the heart to 
accommodate more blood volume in order to maintain stroke volume and cardiac output. 
However, as time passes, the continual increase in blood volume can lead to eccentric 
hypertrophy and volume overload associated with systolic heart failure. On the other hand, had 
TTE measurements shown that LV mass increased while the diameter (LVEDD) had not, it 
would have been indicative of concentric LV hypertrophy resulting from significant thickening 
of the heart muscle in the left ventricle. 
 Further evidence of Eccentric remodeling was paralleled by calculating the index of 
Eccentric Remodeling: 
  Index of Eccentric Remodeling = (AWDT + PWDT) / LVEDD    
 Sham operated mice: (0.86 + 0.88) / 4.07 = 0.427 
 Control group mice: (0.47 + 0.99) / 6.38 = 0.229 
 Low dose OLT-treated mice: (0.47 + 1.01) / 5.71 = 0.259 
 High dose OLT-treated mice: (0.51 + 0.98) / 6.13 = 0.229 
By inputting the corresponding TTE values seen in Tables 3, 4, 5, and 6 into the formula we see 
that all mice groups that underwent nonreperfused AMI surgery display a lower index of 
eccentric remodeling (when compared to sham operated mice) demonstrating an increase in LV 
diameter along with a thinner LV wall. Thus, further indicating that eccentric LV hypertrophy 








Table 3: Left Ventricular Structural Parameters of Group 1 Mice (MI + 3.75g/kg OLT Diet)  
         3 days post-AMI           4 wks post-AMI           10 wks post-AMI        % Change (3d to 10wks) 
N=                  8              8                     8         8 
EDD (mm)           4.63  0.16       5.87  0.42  5.71  0.46               23.3% ↑ 
ESD (mm)            4.02  0.20       5.18  0.38  5.21  0.33  29.6% ↑ 
AWDT (mm)            0.55  0.06       0.42  0.04  0.47  0.08              -14.5% ↓ 
PWDT (mm)            0.89  0.08       0.97  0.20  1.01  0.08  13.5% ↑ 
AWST (mm)            0.57  0.06       0.42  0.04  0.48  0.10              -15.8% ↓ 
PWST (mm)            1.30  0.15       1.40  0.24  1.40  0.12  7.70% ↑ 
FS (%)            13.5  1.77       11.6  1.92  10.5  2.45              -22.2% ↓ 
EF (%)            28.4  3.66       24.4  3.74  22.6  4.96              -20.4% ↓ 
HR (bpm)            379.9  50.4      316.3  77.1  311.5  51.2              -18.0% ↓ 
Calc. LV Mass (mg)      104.4  9.54      151.0  25.7  157.5  34.3  50.0% ↑   
Note: Values are Mean  SD; EDD, End diastolic diameter; ESD, End systolic diameter; AWDT, anterior wall 
diastolic thickness; PWDT, posterior wall diastolic thickness; AWST, anterior wall systolic thickness; PWST, 
posterior wall systolic thickness; FS, fractional shortening; EF, ejection fraction; HR, heart rate.  
 
Table 4: Left Ventricular Structural Parameters of Group 2 Mice (MI + 7.50g/kg OLT Diet) 
         3 days post-AMI           4 wks post-AMI           10 wks post-AMI        % Change (3d to 10wks) 
N=                  7              7                     7         7 
EDD (mm)           4.61  0.17       6.14  0.77  6.13  0.58  33.0% ↑ 
ESD (mm)           4.01  0.17       5.52  0.85  5.42  0.73  35.2% ↑ 
AWDT (mm)           0.55  0.07       0.46  0.07  0.51  0.06              -7.27% ↓  
PWDT (mm)           0.81  0.16       0.89  0.19  0.98  0.16  21.0% ↑  
AWST (mm)           0.58  0.08       0.47  0.08  0.51  0.07              -12.1% ↓ 
PWST (mm)           1.17  0.23       1.17  0.25  1.39  0.23  18.8% ↑ 
FS (%)            13.0  2.00       10.1  3.85  11.9  4.10              -8.46% ↓ 
EF (%)            27.9  4.34       22.1  7.88  24.7  8.20              -11.5% ↓ 
HR (bpm)           439.4  61.3      305.7  60.7  334.0  45.9              -24.0% ↓ 
Calc. LV Mass (mg)      96.5  16.7       161.6  49.0   180.4  46.2  86.9% ↑   
Note: Values are Mean  SD; EDD, End diastolic diameter; ESD, End systolic diameter; AWDT, anterior wall 
diastolic thickness; PWDT, posterior wall diastolic thickness; AWST, anterior wall systolic thickness; PWST, 
posterior wall systolic thickness; FS, fractional shortening; EF, ejection fraction; HR, heart rate.  
 
 
Table 5: Left Ventricular Structural Parameters of Group 3 Mice (MI + SD Diet) i.e. Control 
         3 days post-AMI           4 wks post-AMI           10 wks post-AMI        % Change (3d to 10wks) 
N=                  7              7              7         7 
EDD (mm)           4.83  0.41       5.99  0.58      6.38  0.69  32.1% ↑  
ESD (mm)            4.24  0.37       5.47  0.61  5.62  0.64  32.5% ↑  
AWDT (mm)            0.53  0.07       0.49  0.11  0.47  0.08              -11.3% ↓ 
PWDT (mm)            0.89  0.11       1.00  0.20  0.99  0.14  11.2% ↑ 
AWST (mm)            0.55  0.06       0.53  0.24  0.45  0.08              -18.2% ↓ 
PWST (mm)            1.29  0.19       1.37  0.17  1.39  0.21  7.75% ↑ 
FS (%)                   12.1  2.19       8.43  3.20  10.4  2.30              -14.1% ↓ 
EF (%)            26.4  4.28       18.9  6.84  21.9  4.95              -17.1% ↓ 
HR (bpm)            400.0  55.6      351.7  62.8  312.1  56.2               -22.0% ↓ 
Calc. LV Mass (mg)      110.5  16.0       169.5  25.0  187.2  35.7  69.4% ↑ 
Note: Values are Mean  SD; EDD, End diastolic diameter; ESD, End systolic diameter; AWDT, anterior wall 
diastolic thickness; PWDT, posterior wall diastolic thickness; AWST, anterior wall systolic thickness; PWST, 






Table 6: Left Ventricular Structural Parameters of Group 4 Mice (Sham + SD Diet)  
         3 days post-AMI           4 wks post-AMI           10 wks post-AMI        % Change (3d to 10wks) 
N=    6              6           6         6 
EDD (mm)           3.97  0.26     4.07  0.25   2.52% ↑ 
ESD (mm)           2.58  0.22     2.85  0.28   10.5% ↑ 
AWDT (mm)           0.80  0.09        0.86  0.09   7.50% ↑ 
PWDT (mm)           0.83  0.09     0.88  0.08   6.02% ↑ 
AWST (mm)           1.28  0.10     1.27  0.10  -0.78% ↓  
PWST (mm)           1.20  0.12     1.29  0.15     7.50% ↑ 
FS (%)            34.8  3.97     30.2  3.49  -13.2% ↓ 
EF (%)            64.3  5.13     57.7  4.93  -10.3% ↓ 
HR (bpm)           407.8  78.7    413.0  87.3   1.28% ↑ 
Calc. LV Mass (mg)      95.3  20.1     107.6  17.0   12.9% ↑ 
Note: Values are Mean  SD; EDD, End diastolic diameter; ESD, End systolic diameter; AWDT, anterior wall 
diastolic thickness; PWDT, posterior wall diastolic thickness; AWST, anterior wall systolic thickness; PWST, 
posterior wall systolic thickness; FS, fractional shortening; EF, ejection fraction; HR, heart rate. 
 
3.3 The Effects of OLT1177 on Contractile Reserve   
 Throughout this 10-week study, LV contractile reserve / ß-adrenergic response was 
measured twice as a percent change at 4-weeks and 10-weeks post-AMI. At 4-weeks post-AMI, 
both experimental OLT-treated mice groups and the control diet group were administered 
isoproterenol (i.p.) immediately following TTE assessment. From Figure 17 we see that both 
OLT-treated mice groups 3.75 gr/kg OLT and 7.50gr/kg OLT (when compared to the control 
group) had noticeably greater contractile reserve and thus greater ß-adrenergic responses to 
isoproterenol (+26  11% vs +14  10%, P<0.46) and (+31  10% vs +14  10%, P < 0.27) 
respectively. Whereas control diet mice exhibited a blunted ß-adrenergic response to 
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Figure 17: Contractile reserve assessment at 4 weeks after nonreperfused AMI surgery.  
 
 At 10-weeks post-AMI, both OLT-treated mice groups, the control group, and sham- 
operated mice were administered isoproterenol i.p. immediately following TTE assessment. 
From Figure 18 and 19 we see that low dose OLT-treated mice (3.75 gr/kg OLT) when 
compared to the control group mice displayed a significantly greater ß-adrenergic response and 
LVEF percent increase (33  11% vs 9  7% P < 0.05) and LVFS percent increase (34  10% vs 
4  6%, P < 0.05). Figure 18 also shows that high dose OLT-treated mice (7.50 gr/kg OLT) when 
compared to control diet group mice displayed a significantly greater ß-adrenergic response and 
LVEF percent increase (40  6% vs 9  7%, P < 0.005) and LVFS percent increase (41  7% vs 
4  6%, P < 0.005) (Figure 19). Whereas the control diet mice, when compared to sham-operated 
mice, exhibited a significantly blunted ß-adrenergic response to isoproterenol (9  7% vs 28  
4% LVEF, P<0.05). The significant percent increases of LVEF and LVFS, which were seen in 
both OLT-treated mice groups when compared to the control group, suggests that OLT1177 had 
a significant effect on restoring the contractile reserve and ß-adrenergic response after AMI 















OLT 3.75 gr/kg (N=8)
OLT 7.50 gr/kg (N=7)
Isoproterenol Challenge 10 weeks post-AMI
% increase LVFS
Sham Control Diet OLT 3.75 gr/kg OLT 7.50 gr/kg
* p<0.005 vs sham
# p<0.05 vs control diet














OLT 3.75 gr/kg (N=8)
OLT 7.50 gr/kg (N=7)
*
##
Isoproterenol Challenge 10 weeks post-AMI
% increase LVEF
#
* p<0.05 vs sham
# p<0.05 vs control diet







































Figure 19: LVFS Contractile reserve assessment at 10 weeks after nonreperfused AMI surgery. 
 
3.4 The Effects of OLT1177 on Diastolic Function 
 Eight days after the 10-week TTE assessment, the cardiac function of all surviving mice 
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LV End Diastolic Pressure 10 weeks post-AMI
enough to record LV catheterization values during this procedure). The principle parameter that 
was measured was LV end diastolic pressure (LVEDP). 
 From these LV catheterization measurements (Figure 20), we see a greater degree of 
diastolic dysfunction in control group mice, as evidenced by the significantly higher LVEDP 


















Figure 20: LV catheterization assessment of LVEDP, LV end diastolic pressure at ∼11 weeks after 
nonreperfused AMI surgery.  
 
Figure 20 also demonstrates that both OLT-treated mice groups (3.75 gr/kg OLT and 7.50gr/kg 
OLT) and sham-operated mice displayed similar LV end-diastolic pressures. Thus, indicating 
that treatment with OLT1177 3.75 gr/kg or 7.50 gr/kg led to the preservation of diastolic 
function with a significantly lower LVEDP when compared to the control group (3.2  0.5 
mmHg, or 4.5  0.5 mmHg vs 10.0  1.6 mmHg in standard diet; P<0.005 and P<0.009).  
 All things considered, the elevated filling pressures (LVEDP) in control group mice, can 





mice groups seem to suggest that OLT1177 treatment is effective at preventing the increase in 
filling pressure due to diastolic dysfunction. 
 
3.5 Chapter Summary 
 The general aim of our study was to assess the effects of OLT1177 on improving cardiac 
function, cardiac remodeling, and contractile reserve. For this purpose, our experimental groups 
were fed an OLT1177-enriched diet (3.75g or 7.50g of OLT1177 per kg of food) starting 1 week 
after nonreperfused AMI surgery until the end of the 10-week experiment.   
 At the end of 10 weeks 2 of 10 mice (20%) mice had died in the OLT 3.75 gr/kg group, 
as compared with 2 of 9 mice (22%) in the OLT 7.5 gr/kg group, 3 of 10 mice (30%) in standard 
diet, and 0 of 6 (0%) in sham-operated mice. Our results from this study, taken from 
transthoracic echocardiography, isoproterenol challenge, and LV catheterization, show that 
control group mice (when compared to sham operated mice) displayed a significant increase in 
cardiac remodeling in the form of LV dilatation ([LVEDD] 6.40.3mm vs 4.070.1mm, P 
<0.0005) and eccentric LV hypertrophy ([LV mass] 187.113.5mg vs 107.66.9, P<0.0005), a 
significant decrease in systolic function as evidenced by a significantly reduced LVEF 
(21.91.9% vs 57.72.0%, P<0.0005), a significant loss in contractile reserve/ß-adrenergic 
response([%change in LVEF] 8.77.2% vs 28.14.3%, P<0.05), and a significant decrease in 
diastolic function in the form of increasing filling pressures ([LVEDP] 10.01.6mmHg vs 
2.80.5mmHg, P<0.005)   
 Whereas data from our experimental mice groups treated with a 3.75 gr/kg or 7.50 gr/kg 





restoration of contractile reserve (percent increase in LVEF after isoproterenol challenge (33  
11% or 40  6% vs +9  7 % in standard diet; P<0.05 and P<0.005 respectively). Treatment with 
OLT 3.75 gr/kg or 7.5 gr/kg also led to preservation of diastolic function (left ventricular end-
diastolic pressure 3.2  0.5 mmHg, or 4.5  0.5 mmHg vs 10.0  1.6 mmHg in standard diet; 
P<0.005 and P<0.009). The data from our experimental OLT-treated mice groups show that 
these effects were independent of the effects of ventricular remodeling, systolic function, and 























CHAPTER 4: Discussion 
 How inflammation, dependent on the NLRP3 inflammasome, contributes to AMI, cardiac 
remodeling, and HF progression, is a continuous and complex topic of research. Especially since 
inflammation has been shown to be both beneficial and detrimental in processes following 
myocardial injury. To further elucidate the efficacy of a novel targeted anti-inflammatory 
strategy, this present study was designed to investigate both the role of the NLRP3 
inflammasome after a nonreperfused AMI, and the effects that inhibiting NLRP3 could have on 
blunting aberrant NLRP3 pro-inflammatory signaling following a severe AMI, thereby 
potentially limiting the pathophysiological processes that occur in ischemic heart failure.    
 The results of this current study so far have shown that NLRP3 inhibition in OLT-treated 
mice significantly preserved contractile reserve/ß-adrenergic response, as well as prevented left 
ventricular diastolic dysfunction in a large nonreperfused anterior AMI, while having no effect 
on limiting cardiac enlargement (dilatation) and left ventricular systolic dysfunction (reduced 
LVEF). The majority of these results are in line with numerous past studies that have targeted 
different levels of the NLRP3 molecular pathway, whether targeting downstream products such 
as IL-1ß (Abbate et al., 2008), and caspase-1 (Frantz et al., 2003), or the more upstream targets 
such as P2X7 receptor (Mezzaroma et al., 2011), MyD88  (B. Van Tassell et al., 2011), and the 
NLRP3 inflammasome (Mezzaroma et al., 2011; Toldo et al., 2019). 
 As mentioned previously, the findings from a murine ischemia-reperfusion injury model 
study by Toldo et al. in 2019 confirmed the potential clinical translational value of utilizing 
OLT1177 as a cardioprotective strategy following myocardial injury. The findings from this 
ischemia-reperfusion injury model study showed OLT177 having a reducing effect on cardiac 





caspase-1 activity. This previous study was also key in determining that intraperitoneal injection 
of OLT1177 reaches maximal efficacy when given within one hour after reperfusion. In light of 
these results, our study utilized OLT1177 in a long-term and more severe ischemic injury model. 
We would expect NLRP3 inflammasome activation, oligomerization, and release of pro-
inflammatory cytokines/signaling to have already been initiated and propagated by the time 
OLT1177 diet was administered in our subjects. Thus, focusing on the efficacy of targeting the 
upstream NLRP3 inflammasome by way of OLT1177 NLRP3 inhibition 1 week after myocardial 
injury.   
 One particular study with a similar experimental design and results was conducted in 
2014 by Toldo et al. In this study a nonreperfused AMI murine model was also used, along with 
a mouse monoclonal antibody raised against mouse IL-1ß (10mg/kg) which was injected (i.p.) 
one week after surgery for 9 weeks/once a week. The main findings from utilizing an IL-1ß 
blockade strategy showed analogous results in regard to the significant preservation of diastolic 
function and restoration of contractile reserve, while having no significant effect on cardiac 
enlargement (Toldo et al., 2019). Where our results differ are on the positive effects that IL-1ß 
blockade had on preserving systolic function. Possible reasons for this divergence can be 
attributed to the differences in dosages, bioavailability, and efficacy of each experimental drug. 
Another possible explanation can be due to differences in targets, with OLT1177 targeting the 
more upstream NLRP3 inflammasome, whereas the IL-1ß antibody was directed against the 
more downstream pro-inflammatory IL-1ß cytokine. On that account, it would seem plausible to 
suggest that 1 week after a nonreperfused AMI, NLRP3 activation, oligomerization, and release 
of cytokines such as IL-1ß may have already led to an enhanced post-infarction inflammatory 





more effective at limiting systolic dysfunction due to targeting chronic IL-1ß activity, which in 
previous studies has been shown to promote adverse cardiac remodeling and systolic dysfunction 
(Bujak et al., 2008; Ørn et al., 2012). Nevertheless, without a side-by-side comparison analyzing 
caspase-1 activity and cytokine levels, it would be difficult to fully ascertain the effectiveness of 
each drug on systolic function.   
 Another study that used a nonreperfused AMI murine model was conducted by Marchetti 
et al. in 2015 (Marchetti et al., 2015). Although this study had a shorter duration, their results 
after injecting an NLRP3 inhibitor, a small molecule referred to as 16673-34-0 (100mg/kg) once 
a day for 7 days following AMI surgery, show that the NLRP3 inhibitor, initiated after 
myocardial ischemia, limited both cardiac enlargement and LV systolic dysfunction. Where our 
study design and results differ from this study are on the positive effects that 16673-34-0 has on 
limiting cardiac enlargement and preserving LV systolic function. A possible explanation for this 
difference can be attributed to the timing of administration, in which 16673-34-0 was applied the 
same day of the AMI, whereas in our study OLT1177 being applied 1 week after the AMI. 
Another likely reason can be attributed to the duration of the study. When comparing a 10-week 
nonreperfused AMI to a 1-week nonreperfused AMI it would be reasonable to expect to see a 
more a severe form of adverse cardiac remodeling, with higher levels of caspase-1 activity 
(mRNA synthesis) which according to a previous study by Mezzaroma et al. increases 
severalfold in the heart 3-7 days after an AMI (Mezzaroma et al., 2011) and higher levels of IL-
1ß which has been shown to amplify the inflammatory response leading to higher degrees of 
apoptosis, LV systolic dysfunction and severe cardiomyopathy in the mouse (Mezzaroma et al., 





 This present study had several potential drawbacks and limitations. Some of the more 
common limitations seen in preclinical studies revolve around the use of mice, such as using 
only one breed, using only relatively young healthy male mice, and having a small number of 
subjects. For future studies, performing experiments on mice with other co-morbidities such as 
diabetes mellitus, obesity, advanced age, or hypertension to simulate the present population most 
at risk of developing cardiovascular diseases could be a way to limit these drawbacks. Another 
limitation of this study is the subjective variability in transthoracic echocardiogram 
measurements of LV dimensions and function. 
 Some of the more unique limitations that occur in our study are related to the method of 
oral drug administration. As referenced earlier, our study’s experimental drug was admixed into 
our subjects’ diet. With this form of administration potential drawbacks can occur. For example, 
we noticed that both experimental mice groups during the first two-three weeks consumed a 
lower amount of food containing OLT1177, which could be a potentially confounding feature of 
the experiment. One way to address this limitation for future studies would be to implement 
more precise and accurate drug administration methods, such as oral gavage or intraperitoneal 
injections, as well as measuring test subjects’ blood/plasma regularly to ensure that the 
appropriate therapeutic range of the experimental drug is being met throughout the study.  
 Another limitation of this study was not measuring inflammatory cytokine levels as done 
in previous studies. Although this is a notable limitation, based on our results when compared to 
findings from previous studies (Marchetti, Swartzwelter, Gamboni, et al., 2018b) (Toldo et al., 
2019) we infer that OLT1177 admixed into the experimental groups’ diet was effective at 
inhibiting the NLRP3 inflammasome’s activity. Furthermore, our results give us reason to 





reduced caspase-1 activity, less IL-1ß and IL-18 released, less pyroptotic cell death, and overall a 
decrease in sterile inflammatory response. To address this limitation for future studies, mRNA 
analysis of caspase-1 activity or cytokine levels (IL-1ß or IL-18), whether by Western blot 
densiometric analysis or ELISA assay, would prove useful in helping to quantify the effects of 
OLT1177 on post-infarction inflammatory response.   
 Despite these limitations, the results presented in this study show that NLRP3 inhibition 
with OLT1177 can restore contractility reserve/ß-adrenergic responsiveness and prevent left 
ventricular diastolic dysfunction after a large non-reperfused anterior AMI in mice, thereby 



















CHAPTER 5: Conclusion 
 There is currently an urgent need to develop safe and effective therapeutic strategies to 
prevent or treat heart failure. This need is drastically intensified in patient populations that have a 
large myocardial infarction, do not receive effective reperfusion therapies in the appropriate 
therapeutic window of time, as well as in patients with other comorbidities that lessen the effects 
of reperfusion therapies. Based on the results from this present study and previous ones, reducing 
the aberrant NLRP3 inflammasome signaling and the resulting exuberant inflammatory response 
that follows a myocardial injury is a promising strategy. Therefore, these patients who are most 
at risk of developing post-AMI adverse cardiac remodeling and heart failure would potentially 
benefit the most from an NLRP3 inhibitor such as OLT177.  
 Even so, there are currently no targeted anti-inflammatory strategies routinely used for 
preventing the inflammatory and pathophysiological processes that occur after an acute 
myocardial infarction and during heart failure. To address this void, studies in the last ten years, 
such as the CANTOS trial (Ridker et al., 2017), VCU-ART (Abbate et al., 2010), VCU-ART2 
(Abbate et al., 2013), and REDHART (B. W. Van Tassell et al., 2017) have provided evidence in 
support of implementing the concept of utilizing IL-1 blockade to inhibit the NLRP3 mediated 
inflammatory response, in order to improve the outcomes of patients with severely damaged 
hearts. With continued efforts, and further elucidation of the mechanisms and inflammatory 
signaling processes that occur after a myocardial injury, more clinical trials investigating 
inflammation as a potential target for therapeutic interventions are on their way. 
 Regarding the future translational value of utilizing OLT1177, one recent study has 
shown promising anti-inflammatory effects of utilizing OLT1177 and a good safety profile in 





effects of OLT1177 (100mg dapansutrile capsules) in patients with systolic heart failure. 
Although the results have not yet been published, if this study was able to confirm a protective 
effect brought about by inhibiting the NLRP3 inflammasome, it follows that continued clinical 
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